Brand Products Offer More Options for Heart Failure Treatment With Chart: Current Market Access to Chronic Heart Failure Medications

Treatment for heart failure still relies significantly on tried-and-true generic drugs, but new brand-name entrants — including Novartis’ Entresto (sacubitril/valsartan) and Amgen’s Corlanor (ivabradine) — are important additions to prescribers’ clinical arsenals against the high-mortality condition, industry insiders say.

In fact, a newly approved expanded indication for Entresto, plus more products recently approved and in the pipeline, could shift the balance more toward brand-name drugs in heart failure treatment, the insiders say.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
June 13

News Briefs: State Officials Urge SCOTUS Review of PBM Regulation Case

READ MORE
scientist-in-lab
June 13

Midsize Plans Struggle to Pay for Cell, Gene Therapies, Execs Say

READ MORE
injector-pen
June 13

Medicaid Programs Are Slow to Cover GLP-1s, but That Could Soon Change

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today